Triazole derivatives as tachykinin receptor antagonists

US7320994B2 · kind B2 · utility

Assignee

• ELI LILLY AND COMPANY · US

Inventors

• Albert Amegadzie · Moorpark, US
• Kevin Matthew Gardinier · Fishers, US
• Erik James Hembre · Indianapolis, US
• Jian Hong · Shanghai, CN
• Louis Nickolaus Jungheim · Indianapolis, US
• Brian S. Muehl · Indianapolis, US
• David Michael Remick · Indianapolis, US
• Michael Alan Robertson · Indianapolis, US
• Kenneth A. Savin · New York, US

Key dates

• Filing date: Apr 22, 2003
• Grant date: Jan 22, 2008
• Expiry date: Jun 6, 2024

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This application relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and its use as an inhibitor of the NK-1 subtype of tachykinin receptors, as well as a process for its preparation and intermediates therefor. (I) wherein: D is a C1-C3 alkane-diyl; R1 is phenyl, which is optionally substituted with one to three substitutents independently selected from the group consisting of halo, C1-C4 alkyl, C1-C4 alkoxy, cyano, difluoromethyl, trifluoromethyl, and trifluoromethoxy; R4 is a radical selected from the group consisting of: (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH)